Prévenir le VIH par la PrEP : enjeux et perspectives

ONUSIDA, 2019 Cazein, 2019 2018 ONUSIDA, 2019 Haute Autorité de santé, 2019 Billioti de Gage, 2019 Sagaon-Teyssier, 2016, Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial, AIDS Care, 28, 48, 10.1080/09540121.2016.1146653 Molina, 2019, Incidence of HIV-infection with daily or on-demand PrEP with TDF/FTC in Paris area. Update from the ANRS Prevenir Study Grulich, 2018, Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study, Lancet HIV, 5, e629, 10.1016/S2352-3018(18)30215-7 Patrick, 2018, The impact of pre-exposure prophylaxis with TDF/FTC on HIV diagnoses, 2012-2016, United States Hayes, 2019, Estimating the ‘PrEP Gap’: how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019, Eurosurveillance, 24, 2, 10.2807/1560-7917.ES.2019.24.41.1900598 European Centre for Disease Prevention Control, 2019 Blumenthal, 2014, Will risk compensation accompany pre-exposure prophylaxis for HIV?, Virt Ment VM, 16, 909 Fonner, 2016, Effectiveness and safety of oral HIV preexposure prophylaxis for all populations, AIDS Lond Engl, 30, 1973, 10.1097/QAD.0000000000001145 Traeger, 2018, Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis, Clin Infect Dis, 67, 676, 10.1093/cid/ciy182 Traeger, 2019, Association of HIV pre-exposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection, JAMA, 321, 1380, 10.1001/jama.2019.2947 Powell, 2019, Update on HIV pre-exposure prophylaxis: effectiveness, drug resistance, and risk compensation, Curr Infect Rep, 21, 28, 10.1007/s11908-019-0685-6 Younger, 2019, Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collafrboration: implications for PrEP, Antivir Ther, 24, 211, 10.3851/IMP3302 Lions, 2019, Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort, BMC Infect Dis, 19, 278, 10.1186/s12879-019-3915-5 Pérez-Figueroa, 2015, Acceptability of PrEP uptake among racially/ethnically diverse young men who have sex with men: the P18 study, AIDS Educ Prev, 27, 112, 10.1521/aeap.2015.27.2.112 Eaton, 2017, Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using prep among black and white men and transgender women who have sex with men, AIDS Behav, 21, 1236, 10.1007/s10461-017-1690-0 Golub, 2018, Stigma: PrEP implicit and explicit drivers of disparity, Curr HIVAIDS Rep, 15, 190, 10.1007/s11904-018-0385-0 Blackstock, 2017, A cross-sectional online survey of HIV pre-exposure prophylaxis adoption among primary care physicians, J Gen Intern Med, 32, 62, 10.1007/s11606-016-3903-z Deblonde, 2018, HIV testing within general practices in Europe: a mixed-methods systematic review, BMC Public Health, 18, 1191, 10.1186/s12889-018-6107-0 Dyer, 2013, Why don’t healthcare professionals talk about sex? A systematic review of recent qualitative studies conducted in the United Kingdom, J Sex Med, 10, 2658, 10.1111/j.1743-6109.2012.02856.x Petroll, 2017, PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists, AIDS Behav, 21, 1256, 10.1007/s10461-016-1625-1 Calabrese, 2017, Integrating HIV preexposure prophylaxis (PrEP) into routine preventive health care to avoid exacerbating disparities, Am J Public Health, 107, 1883, 10.2105/AJPH.2017.304061 Coelho, 2019, Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline, Lancet HIV, 6, e788, 10.1016/S2352-3018(19)30238-3 Mayer, 2020, Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial, Lancet Lond Engl, 396, 239, 10.1016/S0140-6736(20)31065-5 Haute Autorité de santé, 2017 Krakower, 2020, Tenofovir alafenamide for HIV preexposure prophylaxis: what can we DISCOVER about its true value?, Ann Intern Med, 172, 281, 10.7326/M19-3337 PrEPWatch. Dapivirine Vaginal Ring. https://www.prepwatch.org/nextgen-prep/dapivirine-vaginal-ring/. Accès au site le 14/01/2020 [Date de mise à jour de la publication est le 13 août 2020]. Landovitz, 2020, HPTN083 in terim results: pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW)